Last reviewed · How we verify
Saline solution, 0.6% — Competitive Intelligence Brief
marketed
Osmotic agent / Ophthalmic decongestant
Ophthalmology
Small molecule
Live · refreshed every 30 min
Target snapshot
Saline solution, 0.6% (Saline solution, 0.6%) — Novaliq GmbH. Hypotonic saline solution (0.6%) reduces corneal edema and improves corneal clarity by osmotically drawing fluid from swollen corneal tissue.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Saline solution, 0.6% TARGET | Saline solution, 0.6% | Novaliq GmbH | marketed | Osmotic agent / Ophthalmic decongestant |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Osmotic agent / Ophthalmic decongestant class)
- Novaliq GmbH · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Saline solution, 0.6% CI watch — RSS
- Saline solution, 0.6% CI watch — Atom
- Saline solution, 0.6% CI watch — JSON
- Saline solution, 0.6% alone — RSS
- Whole Osmotic agent / Ophthalmic decongestant class — RSS
Cite this brief
Drug Landscape (2026). Saline solution, 0.6% — Competitive Intelligence Brief. https://druglandscape.com/ci/saline-solution-0-6. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab